DTaP-Hep B-IPV vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, a Sanofi Company

Conditions

DiphtheriaHepatitis BPertussisPoliomyelitisTetanusWhooping Cough

Phase 2

Pentavalent DTaP-Hep B-IPV

CompletedNCT00133445

National Institute of Allergy and Infectious Diseases (NIAID)Diphtheria, Hepatitis B, Pertussis +2

Start: 2005-12-31End: 2006-08-31Updated: 2011-11-07

Phase 3

A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants

CompletedNCT01177722

Sanofi Pasteur, a Sanofi CompanyDiphtheria, Hepatitis B, Poliomyelitis +2

Start: 2010-08-31End: 2011-12-31Updated: 2014-05-05

Related Papers

A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.

2017-11-0120 citations